Already have an account? Sign in.
Excitement Builds for Skye Bioscience's Potential Weight Loss Game-Changer
Skye Bioscience's promising, safe weight loss drug, nimacimab, earned a "Buy" rating and $20 price target from analysts.
Skye Bioscience's promising, safe weight loss drug, nimacimab, earned a "Buy" rating and $20 price target from analysts.
Biomarkers improved, but Phase 1 data, rivals, and the ZEUS miss kept buyers on the sidelines.
Disney’s television business may face hundreds of layoffs and division mergers as the company shifts focus from cable to streaming.
Shares dropped after Grindr’s $250 million Freddie buy. Near-term margins may dip before the company expects a return above 40%.